NEW YORK, NY – May 9, 2014 – The Cardiovascular Research Foundation (CRF) will hold a special session providing updates on several key cardiovascular trials on Tuesday, May 20 at this year’s EuroPCR meeting. The session will feature studies conducted by the CRF Clinical Trials Center, the academic research organization of CRF. EuroPCR will be held May 20-23, 2014 at the Palais Des Congrès de Paris in France.
Co-chaired by Gregg W. Stone, MD, Co-Director of the Medical Research & Education Division at CRF, and Ori Ben-Yehuda, MD, Executive Director of the CRF Clinical Trials Center, the session will present and discuss the latest investigations on vulnerable plaque, bioresorbable scaffolds, drug-eluting stents, antiplatelet medications, embolic protection stents, and mitral regurgitation.
“The session will focus on some of the most important trials currently in progress in the field of interventional cardiology,” said Dr. Ben-Yehuda. “We are delighted to be presenting here at EuroPCR. Many of our studies are international and we work closely with our European colleagues in advancing the treatment of cardiovascular disease.”
Planned and Ongoing Clinical Trials: A Status Update from the Cardiovascular Research Foundation
Tuesday, May 20, 3:20 – 4:20 PM
PROSPECT II and PROSPECT ABSORB: Providing Regional Observations to Study Predictors of Events in the Coronary Tree
ABSORB IV: A Clinical Evaluation of Absorb Bioresorbable Vascular Scaffolds, the Everolimus-eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects with de novo Native Coronary Artery lesions IV
HORIZONS-AMI II: Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction II
MASTER II: MGuard Prime Stent System Clinical Trial in Patients with Acute STEMI II
COAPT: Cardiovascular Outcomes Assessment of the MitraClip Therapy Percutaneous Therapy for High Surgical Risk Patients